Product
IMI/REL FDC
Aliases
MK-7655A
2 clinical trials
3 indications
Indication
Gram-negative Bacterial InfectionIndication
Hospital-Acquired Bacterial PneumoniaClinical trial
A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative InfectionsStatus: Completed, Estimated PCD: 2020-07-28
Clinical trial
A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaStatus: Completed, Estimated PCD: 2022-07-12